In this three-part series, we will look at how the U.S. Supreme Court’s jurisprudence on patent eligibility has evolved, examine the impact of its March 2012 decision in Mayo Collaborative Services v. Prometheus Labs, Inc. on life sciences patent litigation in lower courts, and discuss what it means for patent eligibility of biologic and biosimilar patents. Read Limin Zheng’s article published in Biosimilar Development here.
“The Numbers Indicate the Russian Olympic Ban Was Too Harsh,” Sports Law360, December 5, 2017, http://www.gcalaw.com/wp-content/uploads/2017/12/the_numbers_indicate.pdf.
“Australian Football Transgender Ban Is Discriminatory,” Sports Law 360, October 16, 2017,
“Would Spock Kneel for the Anthem,” Texas Tribune, October 10, 2017, https://www.tribtalk.org/2017/10/10/would-spock-kneel-for-the-anthem/
In Amgen v. Hospira, issued August 10, the Federal Circuit provided its latest take on the “patent dance” under the Biologics Price Competition and Innovation Act (“BPCIA”). The Federal Circuit sets a low bar for what constitutes “a claim of patent infringement could reasonably be asserted” under BPCIA and allows a reference product sponsor to potentially identify a lot more patents at the beginning of the dance than what it can reasonably assert at the end of the dance, after receiving additional information from the biosimilar applicant. Read Limin Zheng’s article published in Daily Journal here.
“Pepperdine Gay Bias Case—A Loss and a Win for Plaintiffs, Law 360, August 14, 2017, http://www.gcalaw.com/wp-content/uploads/2017/08/SBRM.pdf.
“IAAF Recognition of Intersex Runner Sets Humane Precedent,” Law 360, August 3, 2017, http://www.gcalaw.com/wp-content/uploads/2017/08/iaaf-recognition.pdf
“Case Against Intersex Runner Is Sprinting To Another Loss,” Law360, July 18, 2017, https://www.law360.com/articles/945183
“Trump Transgender Tweet Ignores Medical Findings,” Texas Tribune, July, 28, 2017, http://trib.it/2u2VKmB